Tracer library / [18F]AlF-NOTA-FAPI-04
[18F]AlF-NOTA-FAPI-04
Also written as [18F]AlF-NOTA-FAPI-04; [F-18]AlF-NOTA-FAPI-04
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- NOTA-conjugated FAP inhibitor (FAPI) small molecule, radiolabeled via Al18F chelation
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 41670631
- Clinical application
- PET/CT imaging of fibroblast activation protein expression in oncologic and fibrotic diseases PMID 41670631
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| AllinOne (AiO) Trasis | custom manifold | SPE | 26.4 ± 1.5% decay-corrected | >99.0% | NOTA-FAPI-04 Paite Biotech, Beijing, China | 33816303 2021 Front Oncol AllinOne module (Trasis, Ans, Belgium) was used and modified - the radiochemical yield was 26.4 ± 1.5% (attenuation correction, n = 10) |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- FAPI PET/CT in post-PCI coronary disease: in-stent restenosis characterization, MACE association, and limited short-term modulation by lipid-lowering therapy: FAPI athero trial.2026 · Eur J Nucl Med Mol Imaging · Prospective
- Comparative study of [18F]AlF-NOTA-FAPI-RGD and [18F]FDG/[18F]AlF-NOTA-FAPI-04 PET/CT in renal cell carcinoma.2025 · Theranostics · Clinical study
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Paite Biotech, Beijing
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [18F]AlF-NOTA-FAPI-04, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]AlF-NOTA-FAPI-04.
Get in touchNotes
Added from reverse module search (stage 6); 2 article(s) with F-18. Compound class inferred from precursor name (not stated outright) -- PMID 33816303: 'NOTA-FAPI-04'.